Statin and BP drug pairing tied to less dementia

High blood pressure and high cholesterol are two of the best-established modifiable risk factors for dementia, and enormous numbers of people over 45 take a statin alongside a blood-pressure medicine. What has been far less clear is whether the particular blood-pressure class paired with the statin matters for later brain health. Antihypertensive drugs differ in how they act on the renin-angiotensin system: some increase angiotensin-II formation while others suppress it, and that distinction has been proposed to influence cognition. This study set out to compare dementia risk between those two pairings in real-world prescribing data.

The researchers used the 45 and Up Study, a large population-based prospective cohort in New South Wales, Australia. They included adults aged 45 and over who had both hypertension and dyslipidaemia and were concurrently using a statin and an antihypertensive, with exposure defined by a proportion of days covered of at least 80%. One group used angiotensin-II promoting drugs (ARBs, thiazides, dihydropyridine calcium channel blockers), the other angiotensin-II suppressing drugs (ACE inhibitors, beta-blockers, non-dihydropyridine calcium channel blockers). Baseline characteristics were balanced with 1:1 propensity score matching, giving 34,610 participants, 17,305 per group, mean age 65.8 years, followed for a mean of 12.4 years. Cox models adjusted for diet, physical activity, comorbidities and concomitant medications.

Statin plus an angiotensin-II promoting antihypertensive was associated with a 12% lower risk of dementia (HR 0.88, 95% CI 0.79-0.98) compared with statin plus an angiotensin-II suppressing drug. All-cause mortality was 13% lower in the same comparison (HR 0.87, 95% CI 0.82-0.93). Within the promoting group, rosuvastatin (HR 0.43, 95% CI 0.36-0.50) and atorvastatin (HR 0.74, 95% CI 0.64-0.84) combinations showed greater benefit than simvastatin combinations, and pairings involving ARBs looked better than those involving ACE inhibitors. Effects were consistent across both sexes, but the protective association was observed only in the 65-74 year age group. Findings held across sensitivity analyses, including a competing-risks model accounting for death.

Evidence on specific statin-antihypertensive combinations has been limited, so this large cohort with more than a decade of follow-up adds useful real-world signal to a thin literature. Its design, however, cannot separate the drugs from the reasons doctors chose them: people prescribed one class may differ systematically from those prescribed another in ways propensity matching cannot fully capture, even with adjustment for diet, activity and comorbidity. The age restriction of the effect to the 65-74 group and the wide variation between individual statins also raise questions the data cannot resolve. The authors are explicit that randomised trials are needed to confirm the association and to test the proposed angiotensin-II mechanism.

This is a reason to think the choice of blood-pressure drug class alongside a statin may carry consequences beyond blood pressure and lipids, and that the question deserves proper randomised testing. It is not evidence that changing your prescription would protect your memory, and the size of the individual statin comparisons in an observational dataset should be treated with real caution. Medication class selection is a decision made with the clinician who prescribed it, based on your full risk picture. The broader and better-established point stands: treating blood pressure and cholesterol at all is part of the modifiable dementia risk story.